Background: The role of fundoplication in the prevention of esophageal adenocarcinoma is controversial. Development of cancer is associated with proliferation and anti-apoptosis, for which little data exist regarding their response to fundoplication. Methods: Ki-67 and Bcl-2 expression was assessed in the esophagogastric junction (EGJ) and the distal and proximal esophagus of 20 patients with gastroesophageal reflux disease (GERD) treated by fundoplication and in 7 controls. Endoscopy was performed preoperatively and 6 (20 patients) and 48 months (16 patients) postoperatively. Results: There were positive correlations between Ki-67 and Bcl-2 levels in the EGJ (p > 0.001) and in the distal (p = 0.001) and proximal esophagus (p = 0.013). Compared to the preoperative level, Ki-67 expression was elevated in the distal (p = 0.012) and proximal (p = 0.007) esophagus at 48 months. In addition, compared to control values, Ki-67 expression was lower at the 6-month follow-up in the EGJ (p = 0.037) and the proximal esophagus (p = 0.003), and higher at the 48-month follow-up in the distal esophagus (p = 0.002). Compared to control values, Bcl-2 was lower at 6 months in the EGJ (p = 0.038). Conclusions: Proliferative activity after fundoplication increased in the long term in the distal esophagus despite a normal fundic wrap and healing of GERD.

Keywords:
Anti-apoptosis, Bcl-2, Esophagitis, Fundoplication, Gastroesophageal reflux disease, Ki-67, Proliferation
1.
Lagergren J, Bergström R, Lindgren A, Nyrén O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–831.
2.
Spechler SJ: Barrett’s esophagus. Curr Opin Gastroenterol 1999;15:352–354.
3.
Salo J, Kivilaakso E: Role of luminal H+ in the pathogenesis of experimental esophagitis. Surgery 1982;92:61–68.
4.
Parker S, Tong T, Bolden S, Wingo P: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5–27.
5.
Geboes K: Barrett’s esophagus: the metaplasia-dysplasia-carcinoma sequence: morphological aspects. Acta Gastroenterol Belg 2000;63:7–13.
6.
Souza R, Morales C, Spechler S: Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett’s oesophagus. Aliment Pharmacol Ther 2001;15:1087–1100.
7.
Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, Woodward T, Klingler PJ: Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett’s esophagus. Arch Surg 1997;132:728–733.
8.
Izzo J, Luthra R, Wu T, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA: Molecular mechanisms in Barrett’s metaplasia and its progression. Semin Oncol 2007;34(suppl 1):S2–S6.
9.
Shimizu D, Vallbohmer D, Kuramochi H, Uchida K, Schneider S, Chandrasoma PT, Shimada H, DeMeester TR, Danenberg KD, Peters JH, DeMeester SR, Danenberg PV: Increasing cyclooxygenase-2 (COX-2) gene expression in the progression of Barrett’s esophagus to adenocarcinoma correlates with that of Bcl-2. Int J Cancer 2006;119:765–770.
10.
Whittles C, Biddlestone L, Burton A, Barr H, Jankowski JA, Warner PJ, Shepherd NA: Apoptotic and proliferative activity in the neoplastic progression of Barrett’s oesophagus: a comparative study. J Pathol 1999;187:535–540.
11.
Binato M, Gurski R, Fagundes R, Meurer L, Edelweiss MI: p53 and Ki-67 overexpression in gastroesophageal reflux disease-Barrett’s esophagus and adenocarcinoma sequence. Dis Esophagus 2009;22:588–595.
12.
Vallböhmer D, DeMeester S, Oh D, Banki F, Kuramochi H, Shimizu D, Hagen JA, Danenberg KD, Danenberg PV, Chandrasoma PT, Peters JH, DeMeester TR: Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol 2006;101:1458–1466.
13.
Chen L, Hu C, Gaboury L, Pera M, Ferraro P, Duranceau AC: Proliferative activity in Barrett’s esophagus before and after antireflux surgery. Ann Surg 2001;234:172–180.
14.
Polkowski W, Meijer G, Baak J, ten Kate FJ, Obertop H, Offerhaus GJ, van Lanschot JJ: Reproducibility of p53 and Ki-67 immunoquantitation in Barrett’s esophagus. Anal Quant Cytol Histol 1997;19:246–254.
15.
Lynch D, Clarke A, Jackson P, Axon AT, Dixon MF, Quirke P: Comparison of labelling by bromodeoxyuridine, MIB-1 and proliferating cell nuclear antigen in gastric mucosal biopsy specimens. J Clin Pathol 1994;47:122–125.
16.
Kerkhof M, Steyerberg E, Kusters J, van Dekken H, van Vuuren AJ, Kuipers EJ, Siersema PD: Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett’s esophagus. Cancer Biomark 2008;4:1–10.
17.
Chen X, Ouyang Q, Zhang W, Li XS, Liang HL: The clinical, pathological features and expression of Ki-67 and COX-2 in severe reflux esophagitis and Barrett’s esophagus (in Chinese). Sichuan Da Xue Xue Bao Yi Xue Ban 2005;36:207–209.
18.
Zutter M, Hockenberry D, Silverman G, Korsmeyer SJ: Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 1991;78:1062–1068.
19.
Lauwers GY, Kandemir O, Kubilis PS, Scott GV: Cellular kinetics in Barrett’s epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation. Modern Pathol 1997;10:1201–1208.
20.
Hague A, Moorghen M, Hicks D, Chapman M, Paraskera C: Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367–3370.
21.
Beilstein M, Silberg D: Cellular and molecular mechanisms responsible for progression of Barrett’s metaplasia to esophageal carcinoma. Gastroenterol Clin North Am 2002;31:461–479, ix.
22.
Rantanen T, Salo J, Salminen J, Kellokumpu IH: Functional outcome after laparoscopic or open Nissen fundoplication: a follow-up study. Arch Surg 1999;134:240–244.
23.
DeMeester T: Antireflux surgery in the management of Barrett’s esophagus. J Gastrointest Surg 2000;4:124–128.
24.
Corey K, Schmitz S, Shaheen N: Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus. A meta-analysis. Am J Gastroenterol 2003;98:2390–2394.
25.
Csendes A: Surgical treatment of Barrett’s esophagus: 1980–2003. World J Surg 2004;28:225–231.
26.
Tran T, Spechler SJ, Richardson P, El-Serag HB: Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol 2005;100:1002–1008.
27.
Spechler S, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W: Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA 2001;285:2331–2338.
28.
DeMeester TR, Johnson LF, Joseph GJ, Toscano MS, Hall AW, Skinner DB: Patterns of gastroesophageal reflux in health and disease. Ann Surg 1976;184:459–470.
29.
Savary M, Miller G: Der Oesophagus, Lehrbuch und endoskopischer Atlas. Solothurn, Gassmann, 1977.
30.
Rantanen T, Räsänen J, Sihvo E, Ahotupa MO, Färkkilä MA, Salo JA: The impact of antireflux surgery on oxidative stress of esophageal mucosa caused by gastroesophageal reflux disease: four-year follow-up study. Am J Gastroenterol 2006;101:222–228.
31.
Riddell RH: The biopsy diagnosis of gastroesophageal reflux disease, ‘carditis’, and Barrett’s esophagus, and sequelae of therapy. Am J Surg Pathol 1996;20(suppl 1):S31–S50.
32.
Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996;20:1161–1181.
33.
Haapasalo H, Collan Y, Atkin N, Pesonen E, Seppä A: Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology 1989;15:167–178.
34.
Hong MK, Laskin WB, Herman BE, Johnston MH, Vargo JJ, Steinberg SM, Allegra CJ, Johnston PG: Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett’s esophagus. Cancer 1995;75:423–429.
35.
O’Hanrahan T, Marples M, Bancewicz J: Recurrent reflux and wrap disruption after Nissen fundoplication: detection, incidence and timing. Br J Surg 1990;77:545–547.
36.
Feagins LA, Zhang HY, Hormi-Carver K, Quinones MH, Thomas D, Zhang X, Terada LS, Spechler SJ, Ramirez RD, Souza RF: Acid has antiproliferative effects in nonneoplastic Barrett’s epithelial cells. Am J Gastroenterol 2007;102:10–20.
37.
Jaiswal K, Lopez-Guzman C, Souza RF, Spechler SJ, Sarosi GA Jr: Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett’s cell line. Am J Physiol Gastrointest Liver Physiol 2006;290:G335–G342.
38.
Jiang Z, Gong J, Zhang Z, Qiua Z: Influence of acid and bile acid on ERK activity, PPARγ expression and cell proliferation in normal human esophageal epithelial cells. World J Gastroenterol 2006;12:2445–2449.
39.
Sihvo E, Salminen J, Rantanen T, Rämö OJ, Ahotupa M, Färkkilä M, Auvinen MI, Salo JA: Oxidative stress has a role in malignant transformation in Barrett’s esophagus. Int J Cancer 2002;102:551–555.
40.
Ouatu-Lascar R, Fitzgerald RC, Triadafilopulos G: Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology 1999;117:327–335.
41.
Räsänen JV, Sihvo EIT, Rantanen TK, Ahotupa MO, Färkkilä MA, Harjula A, Salo JA: Gastroesophageal reflux patients’ defective antioxidative capacity in the proximal esophageal mucosa before antireflux surgery and also after 4-year follow-up. Ann Med 2007;16:1–7.
42.
Mastracci L, Grillo F, Zentilini P, Spaggiari P, Dulbecco P, Pigozzi S, Savarino V, Fiocca R: Cell proliferation of squamous epithelium in gastro-oesophageal reflux disease: correlations with clinical, endoscopic and morphological data. Aliment Pharmacol Ther 2007;25:637–645.
43.
Day D: Biopsy Pathology of the Oesophagus, Stomach and Duodenum. London, Chapman & Hall, 1986, pp 11–13.
44.
Petersson F, Franzèn L, Borch K: Characterization of the gastric cardia in volunteers from the general population. Dig Dis Sci 2010;55:46–53.
45.
DeMeester SR, Campos GM, DeMeester TR, Bremner CG, Hagen JA, Peters JH, Crookes PF: The impact of an antireflux procedure on intestinal metaplasia of the cardia. Ann Surg 1998;228:547–556.
46.
Wetscher G, Schwelberger H, Unger A, Offner FA, Profanter C, Glaser K, Klingler A, Gadenstaetter M, Klinger P: Reflux-induced apoptosis of the esophageal mucosa is inhibited in Barrett’s epithelium. Am J Surg 1998;176:569–573.
47.
Chen L, Hu C, Der Sarkissim S, Ferraro P, Pera M, deBlois D, Gaboury L, Duranceau AC: Apoptosis in Barrett’s oesophagus following antireflux surgery. Br J Surg 2002;89:1444–1449.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.